When optimizing your study practice, it is vital to evaluate every trial phase in context.
While new guidance has created a much needed sense of urgency to define a risk-based monitoring approach to clinical trials, there is one critical area of monitoring that cannot be ignored.
Nearly 20 years ago Medidata was built around modernizing data capture and management, which ultimately became Rave. Today, we can confidently say we’re so much more than that.
Unsupervised genomic clustering can pinpoint safety and efficacy signals quickly and accurately...so what is unsupervised genomic clustering?
Last month Medidata celebrated Black History Month, and we took time to come together for our speaker series MediTalk to discuss how our industry can close the diversity gap in clinical trials.